Athersys Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Athersys Contact Number

Athersys, Inc. Our Company Contact Us

Just Now Athersys.com Show details

(216) 431-9900Athersys Headquarters. Athersys, Inc. 3201 Carnegie Avenue Cleveland, OH 44115-2634 T: (216) 431-9900 F: (216) 361-9495

Category: Contact SupportShow more

Athersys Crunchbase Company Profile & Funding

8 hours ago Crunchbase.com Show details

Contact Email [email protected]athersys.com. Phone Number (216)431-9900. Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life. The product development portfolio of the Company includes MultiStem, a stem cell product, which is being

Founded: 1995
Founders: Gil Van Bokkelen, John Harrington

Category: Contact NumberShow more

Athersys, Inc. Home

2 hours ago Athersys.com Show details

At Athersys, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

Category: Home PhoneShow more

Athersys, Inc. Athersys to Host Third Quarter Financial

3 hours ago Athersys.com Show details

Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, November 15, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date November 15, 2021 Time 4:30 p.m. …

Date: November 15, 2021
Phone registration: Call registration link
Live webcast registration: Webcast link
Time: 4:30 p.m. (Eastern Time)

Category: Contact NumberShow more

Phase II Trial Evaluating the Safety and Efficacy of an

3 hours ago Sbir.gov Show details

(216) 431-9900Business Contact. Name: LAURA CAMPBELL Phone: (216) 431-9900 Email: [email protected]athersys.com. and obesity increase the incidence and associated cost of care for CVD Is expected to rise as well By the number of people in US age and over will increase by Despite the high cost of care and prevalence the medical options to treat both AMI and CHF

Category: Contact NumberShow more

Athersys, Inc. Athersys to Host Second Quarter Financial

4 hours ago Athersys.com Show details

Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, August 9, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date August 9, 2021 Time 4:30 p.m. (Eastern …

Category: Contact NumberShow more

Athersys, Inc. Investors

7 hours ago Athersys.com Show details

At Athersys, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

Category: Contact NumberShow more

Athersys Reports Updates on Timing for Japan ARDS and

3 hours ago Finance.yahoo.com Show details

(216) 431-9900[email protected]athersys.com Karen Hunady Director of Corporate Communications and Investor Relations Tel: (216) 431-9900 [email protected]athersys.com. David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858) 717

Category: Contact NumberShow more

Cell Therapy for the Treatment of Acute Respiratory

6 hours ago Sbir.gov Show details

(216) 431-9900Agency Tracking Number: R42AA024003. Amount: $ Business Contact. Name: LAURA CAMPBELL Phone: (216) 431-9900 Allergy and Critical Care and the Division of Cardiothoracic Transplantation at the University of Pittsburgh with Athersys Inc a biotechnology company specialized in the generation of an allogeneic GMP grade bone marrow derived

Category: Cell PhoneShow more

Athersys, Inc. (ATHX) Company Profile & Facts Yahoo …

5 hours ago Finance.yahoo.com Show details

Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio. Corporate Governance Athersys, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 5.

Category: Contact NumberShow more

Athersys to Host Second Quarter Financial Results Call

7 hours ago Businesswire.com Show details

(216) 431-9900Contacts. Ivor Macleod Chief Financial Officer Tel: (216) 431-9900 [email protected]athersys.com Karen Hunady Director of Corporate Communications and Investor Relations Tel: (216) 431-9900 [email protected]athersys.com

Category: Contact NumberShow more

MultiStem Administration for COVID19 Induced ARDS

7 hours ago Clinicaltrials.gov Show details

216-426-3597Recruiting. Akron, Ohio, United States, 44304. Contact: Athersys Clinical Trials Group 216-426-3597 [email protected]athersys.com. Athersys Investigational Site 101. Recruiting. Cleveland, Ohio, United States, 44106. Contact: Athersys Clinical Trials Group 216-426-3597 [email protected]athersys.com. Athersys Investigational Site 102.

Category: Contact NumberShow more

Athersys Reports Third Quarter 2021 Results and Provides

1 hours ago Finance.yahoo.com Show details

(216) 431-9900[email protected]athersys.com. Karen Hunady Director of Corporate Communications & Investor Relations Tel: (216) 431-9900 [email protected]athersys.com. David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858) 717-2310

Date: November 15, 2021
Time: 4:30 p.m. EST
Live webcast registration: Webcast link

Category: Contact NumberShow more

Athersys, Inc. (ATHX): https://register.epo.org

2 hours ago Investorshub.advfn.com Show details

Athersys EPS beats by $0.04 Seeking Alpha - 11/15/2021 4:10:24 PM: Athersys Reports Third Quarter 2021 Results and Provides Corporate Update Business Wire - 11/15/2021 4:05:00 PM: Athersys Q3 2021 Earnings Preview Seeking Alpha - 11/14/2021 5:35:00 PM

Category: Contact NumberShow more

MultiStem® Administration for Stroke Treatment and

7 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03545607

Category: Contact NumberShow more

Athersys Reports Third Quarter 2021 Results and Provides

Just Now Businesswire.com Show details

General and administrative expenses decreased to $3.6 million for the three months ended September 30, 2021 from $3.7 million for the comparable period in 2020. Net loss for the third quarter of

Category: Contact NumberShow more

Form SC 13D/A ATHERSYS, INC / NEW Filed by: HEALIOS K.K.

3 hours ago Streetinsider.com Show details

For purposes of this Section 2(c), in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the

Category: Contact NumberShow more

Tubular Membranes Market 2021 Segment Overview with

9 hours ago Digitaljournal.com Show details

Tubular Membranes Market 2021 Segment Overview with Leading Players – Pentair plc, Berghof Membranes, Duraflow LLC, Hyflux …

Category: Contact NumberShow more

Is Athersys Inc (ATHX) Stock About to Get Hot Wednesday?

5 hours ago Investorsobserver.com Show details

Athersys Inc (ATHX) stock is trading at $1.12 as of 10:35 AM on Wednesday, Dec 8, an increase of $0.04, or 4.21% from the previous closing price of $1.07. The stock has traded between $1.07 and $1.12 so far today. Volume today is less active than usual. So far 348,231 shares have traded compared to average volume of 2,275,411 shares.

Category: Contact NumberShow more

Form 4 ATHERSYS, INC / NEW For: Dec 17 Filed by

6 hours ago Streetinsider.com Show details

FORM 4. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP. Filed pursuant to Section 16 (a) of the Securities Exchange Act of

Category: Contact NumberShow more

Athersys to Present at 2021 Cell & Gene Meeting on the

7 hours ago Finance.yahoo.com Show details

Fidelity Investments reported that the number of 401(k) millionaires—investors with 401(k) account balances of $1 million or more—reached 233,000 at the end of the fourth quarter of 2019, a 16

Category: Cell PhoneShow more

Invitro generation of cardiomyocytes from MAPC SBIR.gov

4 hours ago Sbir.gov Show details

(216) 431-9900Name: WOUTER Vanthof. Phone: (216) 431-9900. Email: [email protected]ATHERSYS.COM. Business Contact. Phone: (216) 431-9900. Research Institution. N/A. Abstract. DESCRIPTION (provided by applicant): The development and institution of stem cell and tissue engineering methodologies hold the potential to target many of the most significant cardiovascular

Category: Contact NumberShow more

Athersys and HEALIOS K.K. Announce Advancement of Their

5 hours ago Businesswire.com Show details

(216) 431-9900Contacts. Ivor Macleod Chief Financial Officer Tel: (216) 431-9900 [email protected]athersys.com Karen Hunady Director of Corporate Communications & Investor Relations Tel: (216) 431-9900 [email protected]athersys.com

Category: Contact NumberShow more

UTHealth in Houston and Athersys Announce Commencement of

2 hours ago Businesswire.com Show details

(216) 431-9900Ivor Macleod Chief Financial Officer Tel: (216) 431-9900 [email protected]athersys.com Karen Hunady Director of Corporate Communications & Investor Relations Tel: (216) 431-9900 [email protected]athersys.com David

Category: Contact NumberShow more

Contact CureVac

5 hours ago Curevac.com Show details

49 7071 9883Contact. CureVac AG Germany, Tübingen. Get directions Arrival and Parking Notes. Headquarters Friedrich-Miescher-Str. 15 72076 Tübingen T +49 7071 9883 – 0 F +49 7071 9883 – 1101. CureVac AG Germany, Frankfurt Site. Get directions. Clinical Development Schumannstr. 27 60325 Frankfurt

Category: Contact SupportShow more

Pediatrician Office Drug Prevention SBIR.gov

5 hours ago Sbir.gov Show details

By 2030, the number of people in US age 65 and over will increase by 80%. Despite the high cost of care and prevalence, the medical options to treat both AMI and CHF are limited. Based on the current clinical data, it would appear highly likely that cell therapy will play a role in the prevention ad treatment of cardiac dysfunction in the

Category: Contact NumberShow more

Athersys Reports Third Quarter 2021 Results and Provides

5 hours ago Bloomberg.com Show details

021-11-15Athersys Reports Third Quarter 2021 Results and Provides Corporate Update A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements

Category: Contact NumberShow more

Implied Volatility Surging for Athersys (ATHX) Stock Options

6 hours ago Finance.yahoo.com Show details

Investors in Athersys, Inc. ATHX need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 14, 2022 $2.00 Call had some of the highest implied

Category: Contact NumberShow more

Athersys Reports Third Quarter 2021 Results and Provides

6 hours ago Marketwatch.com Show details

021-11-15Ivor Macleod Chief Financial Officer Tel: (216) 431-9900 [email protected]athersys.com Karen Hunady Director of Corporate Communications & Investor Relations Tel: (216) 431-9900 [email protected]athersys.com David

Date: November 15, 2021
Time: 4:30 p.m. EST
Live webcast registration: Webcast link

Category: Contact NumberShow more

ClevelandBased Athersys Holding COVID19 Stem Cell

1 hours ago Spectrumnews1.com Show details

Photo courtesy of Athersys. CLEVELAND, Ohio — The World Health Organization considers Acute Respiratory Distress Syndrome, or "ARDS," to be the leading cause of death among COVID-19 infected patients. A Cleveland-based biotechnology company is holding clinical trials to see if its stem cell therapy could help COVID-19 induced ARDS patients.

Category: Cell PhoneShow more

Athersys to Host Third Quarter 2021 Financial Results Call

1 hours ago Biospace.com Show details

CLEVELAND-- ( BUSINESS WIRE )-- Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, November 15, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date.

Category: Contact NumberShow more

Report of PlaceboControlled Clinical Trial Evaluating

7 hours ago Businesswire.com Show details

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.

Category: Contact NumberShow more

ATHERSYS : REPORTS THIRD QUARTER 2021 RESULTS AND …

Just Now Marketscreener.com Show details

Once registered, you will receive the toll-free number, a direct entry passcode and a registrant ID. A replay of the event will be available on the webcast link at www.athersys.com under the investors' section approximately two hours after the call has ended.

Category: Contact NumberShow more

Athersys to Host Second Quarter Financial Results Call

8 hours ago Apnews.com Show details

(216) 431-9900CONTACT: Ivor Macleod. Chief Financial Officer. Tel: (216) 431-9900. [email protected]athersys.comKaren Hunady. Director of Corporate Communications and Investor Relations. Tel: (216) 431-9900. [email protected]athersys.comDavid Schull. Russo Partners, LLC. Tel: (212) 845-4271 or (858) 717-2310. [email protected] KEYWORD: UNITED STATES …

Category: Contact NumberShow more

Optimization of the angiogenic potential of SBIR.gov

3 hours ago Sbir.gov Show details

DESCRIPTION (provided by applicant): Peripheral Vascular Disease (PVD) results from chronic loss of the oxygen supply to the lower limbs due to arterial blockage.

Category: Contact NumberShow more

FDA Authorizes Athersys to Initiate a Pivotal Clinical

8 hours ago Pipelinereview.com Show details

Print. AddThis. In a Phase 1/2 study of MultiStem therapy for the treatment of ARDS, favorable tolerability data and meaningful potential benefits in mortality, ventilator-free days and ICU-free days observed. Company plans to initiate a Phase 2/3 pivotal study in patients with COVID-19 induced ARDS this quarter.

Category: Contact NumberShow more

William Lehmann, Jr. Net Worth, Biography & Insider

8 hours ago Insidertrades.com Show details

(216) 431-9900How do I contact William Lehmann, Jr.? The corporate mailing address for Mr. Lehmann, Jr. and other Athersys executives is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. Athersys can also be reached via phone at (216) 431-9900 and via email at [email protected]athersys.com.

Category: Contact NumberShow more

Athersys Reports Updates on Timing for Japan ARDS and

Just Now Biospace.com Show details

Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K. Published: Nov 12, 2021. Nov. 12, 2021 11:00 UTC. CLEVELAND-- ( BUSINESS WIRE )-- Athersys reports that HEALIOS K.K. (Healios), its development and commercial partner in Japan, provided an update earlier this morning regarding its clinical …

Category: Contact NumberShow more

Athersys Inc. (NASDAQ: ATHX): What’s Next In 2022

2 hours ago Stocksregister.com Show details

According to the data, the short interest in Athersys Inc. (ATHX) stood at 6.98% of shares outstanding as of Dec 14, 2021; the number of short shares registered in Nov 14, 2021 reached 17.18 million. The stock has fallen by -1.01% since the beginning of the year, thereby showing the potential of a further growth.

Category: Contact NumberShow more

Athersys to Host Second Quarter 2021 Financial Results

2 hours ago Biospace.com Show details

CLEVELAND-- ( BUSINESS WIRE )-- Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, August 9, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date.

Category: Contact NumberShow more

Contact Us Greenleaf Family Center

7 hours ago Greenleafctr.org Show details

330-376-9494Greenleaf Family Center 580 Grant Street, Akron, OH 44311 *Client parking and entrance is on Cross Street Office Hours Mon–Thu: 8:30am to 8pm* Friday: 8:30am–noon* *Deaf and Hard of Hearing services are open Mon–Fri from 8:30am to 4:30pm General Phone & Email Phone: 330-376-9494 Fax: 330-376-4525 Toll-free: 1-800-277-9494 Video Phone: 234-525-6176 Email us at

Category: Contact SupportShow more

Athersys Announces Financial Results for Fourth Quarter

2 hours ago Nasdaq.com Show details

020-2021-03Athersys, Inc. announced today its fourth quarter 2020 and annual 2020 financial results and recent highlights. "Despite a difficult operating environment, Athersys has made meaningful progress

Category: Contact NumberShow more

Athersys Number of Employees 20062021 ATHX MacroTrends

5 hours ago Macrotrends.net Show details

Athersys number of employees from 2006 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative

Category: Contact NumberShow more

Report of PlaceboControlled Clinical Trial Evaluating

9 hours ago Ca.finance.yahoo.com Show details

(216) 431-9900[email protected]athersys.com. Karen Hunady Director of Corporate Communications & Investor Relations Tel: (216) 431-9900 [email protected]athersys.com David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858) 717-2310 [email protected]

Category: Contact NumberShow more

ATHX Stock quote for ATHERSYS, INC. MSN Money

3 hours ago Msn.com Show details

European Soft Tissue Repair Market 2021-2028: Leading Players Include WL Gore, Cryolife, Allergan and Athersys - ResearchAndMarkets.com Yahoo Finance 11/15/2021

Category: Contact NumberShow more

John J. Harrington Net Worth, Biography & Insider Trading

7 hours ago Insidertrades.com Show details

The estimated net worth of John J. Harrington is at least $668,754.24 as of June 15th, 2021. Dr. Harrington owns 805,728 shares of Athersys stock worth more than $668,754 as of January 12th. This net worth evaluation does not …

Category: Contact NumberShow more

Report of PlaceboControlled Clinical Trial Evaluating

7 hours ago Biospace.com Show details

CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (NASDAQ: ATHX) announced today that a manuscript reporting data from the Company’s MUST-ARDS clinical trial have been published in the peer-reviewed journal Intensive Care Medicine.MUST-ARDS was a randomized, double-blind placebo-controlled Phase 1/2 trial evaluating the safety and efficacy of MultiStem …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What does Athersys do?

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

What is Athersys’ quality score?

Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio. Athersys, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 5.

What is Athersys'ISS governance qualityscore?

Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio. Athersys, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 5. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 1; Compensation: 9.

Popular Brands

Amazon
Abbvie
Asml
Aia
Att
Apple
Amgen
Adobe
Aptar
Acc
Adidas
Aak